TH Global Capital Closes 4 Major M&A Deals in Australia in 4 Months Including the Sale of The Missing Link to Infosys
7.7.2025 11:59:00 CEST | Business Wire | Press Release
TH Global Capital, an award-winning global boutique investment bank with a presence in 13 countries, has closed four high profile deals in the first four months of 2025, including the sale of The Missing Link to Infosys for 120 million AUD. This marks its tenth cross border transaction in Australia over the past 18 months, cementing its position as the mid-market M&A boutique investment bank of choice in Australia and New Zealand.
- Sale of The Missing Link to Infosys – The Missing Link, an award-winning cybersecurity and IT services provider based in Sydney, will join Infosys to deliver cybersecurity solutions and expand Infosys’s presence in Australia.
- Sale of TMLabs to Coforge – TMLabs, a ServiceNow Elite partner and digital transformation leader headquartered in Sydney, strengthens Coforge’s ServiceNow capabilities in Australia and leverages TMLabs’ existing contracts.
- Sale of Skie to Bluprintx – TH Global Capital’s 13th transaction in ANZ and 12th Salesforce deal globally. Skie, a leading Salesforce consulting partner headquartered in Victoria, adds deep expertise to Bluprintx and strengthens its Salesforce capabilities in the APAC region.
- Sale of PhoenixDX to Alan Allman Associates – PhoenixDX, a leading low-code product engineering firm based in Sydney, enhances France-based Alan Allman Associates’ capabilities and service offerings across the APAC region.
Over the past 24 years, TH Global Capital has closed transactions with leading strategic buyers and private equity funds across 29 countries. Notable ANZ deals include:
- Chamonix IT, a leading Digital Engineering and Microsoft partner, on its sale to Synechron
- Exposé, a premier AI and Data Science company, on its sale to Synechron
- Design + Industry, a world class MedTech Product Design and Engineering consultancy, on its sale to Capgemini
- The Lumery, a leading MarTech consultancy, on its sale to Accenture
- Leonardo, an Automation, BPM & Business Process Transformation specialist, on its sale to UST
- DEK Technologies, a premier Software Engineering and Embedded Systems specialist, on its sale to Endava
- Enable, a leading global ServiceNow partner, on its sale to Fujitsu
- Tenzing, a Management and Technology consultancy, on its sale to Tech Mahindra
Vivek Subramanyam, Founder and CEO of TH Global Capital, said, "Our success in the ANZ region is a testament to our deep market knowledge and extensive global network of buyers and investors. We remain the trusted advisor of choice in the region and globally, committed to driving strategic transactions that create long-term value for our clients."
Stefan Zervides, Director and Head of TMT, ANZ at TH Global Capital, added, “The ANZ region is experiencing a surge in M&A activity, fuelled by innovation and strong investor appetite. We’re proud to be at the forefront of this momentum, advising businesses and connecting them with the right capital and strategic partners globally.”
View source version on businesswire.com: https://www.businesswire.com/news/home/20250707804289/en/
Contacts
Priyanka Patil
priyanka@thglobalcapital.com
(c) 2024 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press Release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:19:00 CEST | Press Release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press Release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press Release
inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and
Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 14:50:00 CEST | Press Release
Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by up to 97% within two months, TP53 and KRAS mutations near undetectable. Immune activity (first six patients): STC-1010 regimen nearly quadrupled cytotoxi
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom